0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics.

      mAbs
      FcRn, FcγRs, pharmacodynamics, B-NHL, pharmacokinetics, CLL, rituximab

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The anti-CD20 antibody rituximab (RTX; Rituxan®, MabThera®) was the first anti-cancer antibody approved by the US Food and Drug Administration in 1997 and it is now the most-studied unconjugated therapeutic antibody. The knowledge gained over the past 15 y on the pharmacodynamics (PD) of this antibody has led to the development of a new generation of anti-CD20 antibodies with enhanced efficacy in vitro. Studies on the pharmacokinetics (PK) properties and the effect of factors such as tumor load and localization, antibody concentration in the circulation and gender on both PK and clinical response has allowed the design of optimized schedules and novel routes of RTX administration. Although clinical results using newer anti-CD20 antibodies, such as ofatumumab and obinutuzumab, and novel administration schedules for RTX are still being evaluated, the knowledge gained so far on RTX PK and PD should also be relevant for other unconjugated monoclonal antibody therapeutics, and will be critically reviewed here.

          Related collections

          Author and article information

          Journal
          23933992
          3896596
          10.4161/mabs.26008

          FcRn,FcγRs,pharmacodynamics,B-NHL,pharmacokinetics,CLL,rituximab
          FcRn, FcγRs, pharmacodynamics, B-NHL, pharmacokinetics, CLL, rituximab

          Comments

          Comment on this article

          scite_